CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background and Objectives CSF biomarkers β‐amyloid 1-42 (Aβ42), phosphorylated tau 181 (p-tau181), total tau (t-tau), and neurogranin (Ng) can diagnose Alzheimer disease (AD) in life. However, it is unknown whether CSF concentrations, and thus their accuracies, are affected by concomitant pathologies common in AD, such as α-synuclein (αSyn). Our primary goal was to test whether biomarkers in patients with AD are altered by concomitant αSyn. We compared CSF Aβ42, p-tau181, t-tau, and Ng levels across autopsy-confirmed AD and concomitant AD and αSyn (AD + αSyn). Antemortem CSF levels were related to postmortem accumulations of αSyn. Finally, we tested how concommitant AD + αSyn affected the diagnostic accuracy of 2 CSF-based strategies: the amyloid/tau/neurodegeneration (ATN) framework and the t-tau/Aβ42 ratio. Methods Inclusion criteria were neuropathologic diagnoses of AD, mixed AD + αSyn, and αSyn. A convenience sample of nonimpaired controls was selected with available CSF and a Mini-Mental State Examination (MMSE) ≥ 27. αSyn without AD and controls were included as reference groups. Analyses of covariance (ANCOVAs) tested planned comparisons were CSF Aβ42, p-tau181, t-tau, and Ng differences across AD and AD + αSyn. Linear models tested how biomarkers were altered by αSyn accumulation in AD, accounting for pathologic β-amyloid and tau. Receiver operating characteristic and area under the curve (AUC), including 95% CI, evaluated diagnostic accuracy. Results Participants were 61 patients with AD, 39 patients with mixed AD + αSyn, 20 patients with αSyn, and 61 controls. AD had similar median age (73 [interquartile range {IQR} = 12] years), MMSE (23 [IQR = 9]), and sex distribution (male = 49%) compared with AD + αSyn age (70 [IQR = 13] years; p = 0.3), MMSE (25 [IQR = 9.5]; p = 0.19), and sex distribution (male = 69%; p = 0.077). ANCOVAs showed that AD + αSyn had lower p-tau181 (F(1,94) = 17, p < 2.6e-16), t-tau (F(1,93) = 11, p = 0.0004), and Ng levels (F(1,50) = 12, p = 0.0004) than AD; there was no difference in Aβ42 (p = 0.44). Models showed increasing αSyn related to lower p-tau181 (β = −0.26, SE = 0.092, p = 0.0065), t-tau (β = −0.19, SE = 0.092, p = 0.041), and Ng levels (β = −0.2, SE = 0.066, p = 0.0046); αSyn was not a significant factor for Aβ42 (p = 1). T-tau/Aβ42 had the highest accuracy when detecting AD, including mixed AD + αSyn cases (AUC = 0.95; CI 0.92–0.98). Discussion Findings demonstrate that concomitant αSyn pathology in AD is associated with lower CSF p-tau181, t-tau, and Ng levels and can affect diagnostic accuracy in patients with AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, coexisting αSyn pathology in AD correlates with lower CSF P-tau181 and NG levels,394 while comorbidity like hypertension lowers plasma Aβ concentration but increases plasma P-tau181 and P-tau217 levels.388,395”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [394]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 9×
“At the same time, low CSF Ng levels may be associated with αSyn with or without ADNC.”
BackgroundMethodInfluentialSelf-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationeffectsize: Estimation of Effect Size Indices and Standardized Parameters
Ben-Shachar, M., Lüdecke, D., & Makowski, D. (2020) · Journal of Open Source Software · doi:10.21105/joss.02815 · Cited by 2,063
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Self-citationMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012
Self-citation
Research works printed but not linked: 2
- Fox J, Weisberg S, Adler D, et al. Package “car”: R Foundation for Statistical Computing; 2012.
- Wheeler B, Torchiano M, Torchiano MM. Package “lmPerm.” R package version. 2016;2.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“393 For example, coexisting α Syn pathology in AD correlates with lower CSF P-tau181 and NG levels, 394 while comorbidity like hypertension lowers plasma A β concentration but increases plasma P-tau181 and P-tau217 levels.”
BackgroundAlpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease
Shim, K. H., Kang, M. J., Youn, Y. C., An, S. S. A., & Kim, S. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01150-0 · Cited by 117
Dickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 70
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Shaw, L. M. J., Korecka, M., Lee, E. B., Cousins, K. A. Q., Vanderstichele, H., Schindler, S. E., Tosun, D., DeMarco, M. L., Brylska, M., Wan, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14264 · Cited by 47
Self-citationFluid and Biopsy Based Biomarkers in Parkinson's Disease
Coughlin, D. G., & Irwin, D. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01379-z · Cited by 47
Self-citation
Metadata
- Authors
- Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Irwin, D. J.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- From the Departments of Neurology (K.A.Q.C., S.A., S.S., D.O., M.G., D.W., C.T.M., A.C.-P., D.J.I.), Pathology and Laboratory Medicine (L.M.S., E.L., J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden; and Department of Neurodegenerative Disease (H.Z.), Institute of Neurology, University College London, UK.
- ORCID
- Venue
- Neurology
- Published
- 2022-11-15
- Volume
- 99
- Issue
- 20
- Pages
- e2303-e2312
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC9694837
- OpenAlex
- W4293694167
- Cited by
- 25
- References
- 48
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 2
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute on Aging (U19AG062418, R01AG068398, P01AG066597, R01AG054519, P30AG072979)
- National Institute of Neurological Disorders and Stroke (R01NS115139)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, alpha-synuclein pathology, cerebrospinal fluid biomarkers, amyloid-beta 42, phosphorylated tau 181, total tau, neurogranin, diagnostic accuracy, postmortem neuropathology, differential diagnosis of dementia
- MeSH terms
- Synucleinopathies, Adolescent, Alzheimer Disease, Child, Humans, Male, Nervous System Diseases, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. https://app.cochat.ai/papers/10.1212/wnl.0000000000201202
- The paper
- Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Irwin, D. J. (2022). CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. Neurology. https://doi.org/10.1212/wnl.0000000000201202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.